Background: Fibrinogen is an essential hemostatic factor and cardiovascular disease risk 3 factor. Early attempts at evaluating the causal effect of fibrinogen on coronary heart disease 4 (CHD) and myocardial infraction (MI) using Mendelian randomization (MR) used single 5 variant approaches, and did not take advantage of recent genome-wide association studies 6 (GWAS) or multi-variant, pleiotropy robust MR methodologies. 7 Methods and Findings: We evaluated evidence for a causal effect of fibrinogen on both 8 CHD and MI using MR. We used both an allele score approach and pleiotropy robust MR 9 models. The allele score was composed of 38 fibrinogen-associated variants from recent 10 GWAS. Initial analyses using the allele score incorporated data from 11 European-ancestry 11 prospective cohorts to examine incidence CHD and MI. We also applied 2 sample MR 12 methods with data from a prevalent CHD and MI GWAS. Results are given in terms of the 13 hazard ratio (HR) or odds ratio (OR), depending on the study design, and associated 95% 14 confidence interval (CI).
1 together, results indicate that even with large sample sizes and multi-variant approaches MR 2 analyses still cannot exclude the null when estimating the causal effect of fibrinogen on CHD, 3 but that any potential causal effect is likely to be much smaller than observed in 4 epidemiological studies. heart disease (CHD) utilized single variants and did not take advantage of modern, multi-9 variant approaches. This manuscript provides an important update to these initial analyses by 10 incorporating larger sample sizes and employing multiple, modern multi-variant MR 11 approaches to account for pleiotropy. We used incident cases to perform a MR study of the 12 causal effect of fibrinogen on incident CHD and the nested outcome of myocardial infarction 13 (MI) using an allele score approach. Then using data from a case-control genome-wide 14 association study for CHD and MI we performed two sample MR analyses with multiple, 15 pleiotropy robust approaches. Overall, the results indicated that associations between may be a small positive effect, however this result needs to be interpreted carefully as the 20 95% confidence intervals were still consistent with a null effect. Multi-variant MR approaches 21 did not suggest evidence of even a small causal effect of fibrinogen on MI. Fibrinogen is an essential component of the clotting and hemostasis system with a strong 3 genetic basis [1] [2] [3] . Although it primarily serves as the precursor to fibrin, it also carries out 4 several other functions, including enhancing platelet aggregation and mediating inflammation 5 [4, 5] . In epidemiologic studies, fibrinogen levels are associated with coronary heart disease 6 (CHD) [6] [7] [8] , myocardial infarction (MI) [9, 10] , ischemic stroke [11, 12] , and abdominal 7 aortic aneurysm [13, 14] . 8 Mendelian randomization (MR) is an instrumental variable analysis method which uses 9 genetic variants as instruments to uncover evidence for a causal relationship between a 10 modifiable risk factor and outcome.
[15] MR studies utilizing a limited number of genetic 11 variants in the FGB promoter have yielded little evidence of a causal effect of fibrinogen on 12 CHD or MI [16] [17] [18] . In a genome-wide association study (GWAS) for fibrinogen, each 13 fibrinogen-associated variant was individually evaluated for association with CHD, but no 14 associations provided substantial evidence of a causal effect [19] . To date MR studies of 15 fibrinogen have been limited to single variant approaches which have not taken into account 16 recent GWAS findings or modern, multi-variant MR methodologies. Here we re-examine the 17 potential for fibrinogen to be a causal biomarker for CHD and MI, taking into account these 18 improved approaches. 
Results

22
For incident CHD there were 3,147 incident events observed in 15,427 participants in the 23 discovery analyses, and 1,482 incident events among the 34,209 participants in the replication 24 analyses. Of the 18,798 participants in the incident MI discovery analyses, 1,711 had an 25 incident MI. For the replication analyses, there were 687 incident MI events out of the 33,288 1 participants. Table 1 contains the distributions of clinical covariates and fibrinogen. The FGB 2 variant rs1800790 (commonly used in previous fibrinogen MR analyses) had a weaker 3 association (by effect size) than the allele score ( Supplemental Table 3 ). In single variant 4 analyses of rs1800790 the estimated causal effect appeared to be centered around the null 5 with little evidence of a causal effect of fibrinogen on CHD or MI ( Supplemental Table 3 ), 6 consistent with published literature. In multi-variant MR using the 2SC model, we observed 7 evidence of a causal association of fibrinogen on incident CHD in the discovery and 8 replication analyses which remained in a combined analysis of all cohorts (HR = 1.75; CI = 9 1.22-2.51; P = 0.002; Figure 2 ). For incident MI, we observed an elevated HR that included 10 the null, even in the combined analysis (HR = 1.45; CI = 0.85-2.49; P = 0.17; Figure 3 ).
11
Pleiotropy robust models 12 In sensitivity analyses four MR methods were used each of which is at least partially robust to 13 horizontal pleiotropy under differing assumptions. For CHD, three of the four models showed 14 a positive effect, albeit smaller than the effect observed in the 2SC model, with the MR 15 PRESSO method having the largest causal OR (OR = 1.18; CI = 0.98, 1.42; Table 2 ). For MI 16 only the MR PRESSO method showed a causal OR > 1 (OR = 1.16; CI = 0.98, 1.38; Table   17 2), again substantially reduced from that observed in the 2SC model. All other models for MI 18 showed little evidence of a causal effect of fibrinogen on MI.
19
As a further test we examined MR associations of fibrinogen on CHD risk using published 20 data available in the MR-Base. While some of the CHD risk factors showed a positive causal 21 effect estimate, none provided substantial evidence for excluding the null after accounting for 22 the number of tests performed ( Supplemental Table 5 ). The attractiveness of fibrinogen as a causal factor in CHD comes from its roles in both 2 thrombosis and inflammation. Fibrinogen is the precursor to fibrin, which interlinks into a 3 mesh that acts as the scaffold of blood clots. Additionally, fibrinogen also has an active role 4 in platelet aggregation,[20] thus contributing to the formation of platelet plugs. By binding the 5 CD11b/CD18 integrin receptor fibrinogen activates the NF-κB pathway [5] , an important 6 pathway in inflammation as well as the formation, destabilization, and rupture of 7 atherosclerotic plaques [21, 22] . As a modifiable risk factor [23] even a small causal effect of 8 fibrinogen on CHD could have substantial public health implications.
9
Using the allele score approach, a 1 g/L higher fibrinogen concentration was causally 10 associated with a HR of 1.75 (CI = 1.22-2.51) in the combined cohort analysis for CHD.
11
However, sensitivity analysis using methods robust to pleiotropy arising from independent 12 effects of SNPs on exposure and outcome (which could invalidate MR analyses) suggested a 13 substantially weaker causal effect on CHD even for the model with the strongest effect 14 estimate (OR = 1.18 per 1 g/L higher fibrinogen; CI = 0.98, 1.42), and the MR Egger model 15 showed virtually no evidence of a causal effect -though the wide 95% confidence interval 16 encompassed effects from all other models. Overall, when accounting for potential horizontal 17 pleiotropy, the accumulated evidence points to a substantially weaker casual effect of 18 fibrinogen on CHD than the observational risk ratio of 1.8 (CI = 1.6, 2.0) previously reported 19 [6]. Using rs1800790 in a single variant MR analysis, there was limited evidence of any 20 causal effect, though the 95% confidence interval could not exclude positive estimated causal 21 effects seen in multi-variant analyses. In combination these analyses suggest that when after 22 accounting for horizontal pleiotropy the effect of fibrinogen on CHD is likely to be small and 23 that current MR estimates of the potential causal effect remain unable to exclude the null 24 despite large sample sizes and the latest methodologies. Previous MR studies assessing the causal effect of fibrinogen on CHD or MI focused 2 exclusively on rs1800790 [24, 25] . In a few studies one additional variant also in the FGB 3 promoter region was examined, however this variant is in nearly complete LD with 4 rs1800790, particularly in Europeans [16, 18] . The allele score was a better predictor of 5 fibrinogen than rs1800790 alone ( Supplemental Table 3 ). Though the allele score estimated 6 a causal effect of fibrinogen on CHD similar to observational studies, much of this appeared 7 to be driven by pleiotropy as estimated effects decreased in models more robust to pleiotropy 8 ( Table 2) . This highlights the need to balance increased power from multi-variant approaches 9 with the potential for increased pleiotropy in these instruments.
10
For the CHARGE cohorts we used exclusively incident cases whereas previous studies 11 utilized populations composed entirely or primarily of prevalent cases. In some instances, the 12 use of prevalent cases may bias MR studies such as if the disease subsequently what is 13 perceived as a disease risk factor, e.g. if CHD leads to higher fibrinogen as opposed to the 14 reverse, then reverse confounding can still occur even in an MR setting [26] . Additionally, if 15 the risk factor were to affect severity of an event, e.g. the fatality of MI, then use of prevalent 16 cases may dilute the MR-estimated causal effect as the most severe cases may not be observed 17 due to being too ill to participate or suffering a fatal event. This type of prevalence-incidence 18 bias is not exclusive to MR analyses [27] [28] [29] . However, care must still be taken when 19 interpreting results from incident case MR studies as the exclusion of prevalent cases is 20 equivalent to conditioning on disease status at baseline. This has the potential to introduce 21 bias in the form of an exclusion restriction violation.
[30] Whether bias is introduced and the 22 degree of confounding are dependent on the actual biological processes that account for the 23 relationship between the genetic instrument(s) chosen, the modifiable risk factor, and outcome 24 in the MR analysis. When performing incident case MR it is best to combine the efforts with 1 MR analyses including prevalent cases and interpret results for both with careful 2 consideration towards their underlying assumptions, strengths, and weaknesses.
3
In general, our results are compatible with previous MR studies, however we use more 4 modern methods, including multi-variant, pleiotropy robust methods, able to produce smaller 5 confidence intervals and which indicate that after accounting for pleiotropy there may be a 6 small positive effect of fibrinogen on CHD. This is particularly true for the methods 7 producing the most precise estimates. However, these results warrant further investigations as 8 confidence intervals for some models were still wide and with results for the single variant 9 and MR Egger analyses possibly more consistent with no causal effect than even a small 10 causal effect. 12 As with all MR studies the causal effects estimated here are based on regression estimates for 13 genetic variants and are only valid, causal estimates under the assumptions of MR. 14 Additionally, causal estimates generated via MR methodologies are for lifelong, genetically 15 determined increases in the exposure, e.g. fibrinogen, which means that caution should be 16 exercised when applying clinical interpretations or attempting to translate results into 17 estimates of an intervention. [31, 32] This study had some overlap between studies involved in 18 the GWAS used to select fibrinogen variants and those used in the MR analyses. Our 19 approach to mitigate this was to replicate the allele score analysis in an independent set of 20 cohorts. For the pleiotropy robust 2-sample MR approaches this overlap was unavoidable, 21 however there was no overlap for the cases which means that unbiased estimates should be 22 obtained [33] . A strength of the study is the use of incident cases for the allele score model 23 approach which reduces the potential for bias from reverse confounding (which can still affect 24 MR studies) and prevalence-incidence bias. Additionally, even though the allele score 25 approach was sensitive to horizontal pleiotropy we used an array of additional approaches that 1 We evaluated 69 variants associated with fibrinogen in at least one of three recent 2 genome/exome-wide association studies [2, 19, 37] for inclusion into the allele score [42] . We 3 applied four criteria to each variant to improve the plausibility that each meets the MR 4 assumptions. First, to ensure that the variants were not correlated with known risk factors for 5 cardiovascular disease (CVD), the Spearman correlation between each of the variants and 6 body mass index (BMI), low-density lipoprotein (LDL) cholesterol, high-density lipoprotein 7 (HDL) cholesterol, type 2 diabetes mellitus (binary), hypertension (binary), and smoking 8 (ever, never, current) was tested within each cohort and any variants with a Spearman 9 correlation greater than 0.10 in any cohort for any of these outcomes were removed. Second, 10 the variants were tested for linkage disequilibrium (LD) with known CHD loci [34, [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] 11 using SNAP from the Broad Institute with LD patterns coming from European ancestry 12 individuals [53] . As no variant had r 2 > 0.20 with a CHD locus, they were considered 13 independent of known CHD loci. Next, we reduced pairs of variants in high LD (r 2 > 0.70) by 14 preferentially retaining those variants that were found in the largest genome-wide scan [37] . 15 Finally, we eliminated any variants that were missing across any of the discovery cohorts, 16 leaving 38 variants that composed the allele score ( Supplemental Table 1 ). We tested the 17 allele score for association with each of the aforementioned CHD risk factors in each cohort 18 as well as in a meta-analysis of all cohorts. The allele score was not associated with any CHD 19 risk factor in the meta-analysis after a Bonferroni correction for the six tests performed (P > 20 0.008; Supplemental Table 2 ). Six variants from the allele score which were unavailable in 21 one or more replication cohorts were removed from the allele score in the replication phase to ensure a consistent allele score in the replication meta-analysis (Supplemental Table 1 ). In a 23 sensitivity analysis these variants were also removed from the discovery cohorts and the 24 causal effect evaluated in a combined meta-analysis. 
11
Strengths and limitations
18
Our initial MR analyses used a two-stage procedure employing a Cox regression model 19 (2SC). To improve power, we regressed fibrinogen on age and sex and used the resulting 20 residuals as input to the 2SC analyses. In the first stage of the 2SC procedure the fibrinogen 21 residuals were regressed on the allele score. In the second stage the predicted values from the 22 first stage regression were associated with incident MI or CHD via a Cox proportional 23 hazards model. This approach is similar to the two-stage predictor-substitution MR approach 24 [55-57], and results from the 2SC model are given per unit (g/L) increase in the fibrinogen 25 residuals. We used a fixed effects model for all meta-analyses since we observed little 1 heterogeneity according to the Q-statistics [58] (P(Q) > 0.05 for all analyses). We also 2 compared associations with our allele score to those obtained using a single variant, FGB -3 455G>A (rs1800790), which is a commonly used variant for fibrinogen MR analyses [16, 18] . 4 We performed sensitivity analyses using four pleiotropy robust methods each of which uses a 5 different approach to partially relax the no horizontal pleiotropy assumption of MR (60,801 prevalent cases and 123,504 controls) and these methods often have lower power to 10 detect effects. For estimates of variant effects on fibrinogen we used fixed-effects meta-11 analysis estimates from the 11 cohorts in these analyses. Since an individual cannot be both a 12 prevalent and incident CHD or MI case at the same sampling, there was no overlap amongst 13 the cases between our incident analyses and the prevalent cases used in the 14 CARDIoGRAMplusC4D GWAS. There would still be some overlap amongst the non-15 cases/controls which could bias estimates towards the null. 16 We also examined whether fibrinogen showed evidence for a causal effect on 7 metabolic 17 CHD risk factors using MR-base (www.mrbase.org), a database of published GWAS 18 available for MR [63] . We focused on metabolic CHD risk factors as initial results indicated 19 that body mass index was the trait with which our allele score showed the strongest evidence 20 for pleiotropy -potentially horizontal (i.e. SNPs affecting fibrinogen and CHD via 21 independent pathways) and vertical (i.e. fibrinogen-associated SNPs also associated with risk 22 factors downstream of fibrinogen) as the associations did not distinguish between the two. Clinical covariates for all participating cohorts. KORA did not have incident CHD data and thus did not participate in these analyses. GENOA and LURIC had too few incident MI cases for analysis. * For FHS 172 individuals were not current smokers but were not distinguished as former vs 
